| Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|---|---|---|---|---|---|
Operating activities | ||||||
Net loss | ||||||
-161,466 | -113,192 | -89,631 | -52,222 | -42,944 | -22,393 | -17,037 |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization expense | ||||||
18,517 | 15,949 | 10,600 | 8,195 | 5,006 | - | - |
Stock-based compensation expense | ||||||
22,202 | 19,524 | 11,176 | 5,989 | 7,316 | - | - |
Provision for doubtful accounts on accounts receivable | ||||||
- | - | 171 | - | - | - | - |
Amortization of premiums and discounts on marketable securities | ||||||
-17 | -248 | -33 | - | - | - | - |
Loss on extinguishment of debt | ||||||
-283 | - | - | - | - | - | - |
Gain on disposal of long-lived assets | ||||||
327 | - | - | - | - | - | - |
Depreciation and amortization expense | ||||||
- | - | - | - | - | 2,894 | 1,520 |
Stock-based compensation | ||||||
- | - | - | - | - | 1,535 | 73 |
Impairment of fixed assets | ||||||
- | - | - | - | 439 | - | - |
Change in fair value of investor rights obligation | ||||||
- | - | - | - | - | - | 1,067 |
Change in fair value of warrant liability | ||||||
- | - | - | - | 1,380 | 131 | 34 |
Common stock issued in exchange for professional services | ||||||
- | - | - | - | 4 | - | - |
Non-cash interest expense | ||||||
- | - | - | 3 | 58 | 104 | 111 |
Changes in operating assets and liabilities: | ||||||
Accounts receivable | ||||||
11,721 | 844 | -2,361 | 3,632 | 4,067 | 1,917 | -973 |
Receivable from Roche | ||||||
8,152 | 1,604 | 403 | - | - | - | - |
Inventory | ||||||
2,576 | 2,446 | 3,183 | 3,046 | 960 | 485 | 318 |
Prepaid expenses and other current assets | ||||||
3,825 | -1,305 | 3,652 | 1,873 | 442 | 237 | 70 |
Other assets | ||||||
-210 | -210 | 267 | 282 | 102 | -10 | 8 |
Accounts payable | ||||||
8,434 | 5,060 | -1,559 | 3,119 | 1,672 | 147 | -338 |
Accrued expenses and other current liabilities | ||||||
15,463 | 8,919 | 4,704 | 1,724 | 1,515 | 1,447 | 580 |
Deferred rent and other non-current liabilities | ||||||
-1,848 | 1,688 | -1,805 | 133 | -1,219 | - | - |
Deferred rent | ||||||
- | - | - | - | - | -109 | - |
Deferred rent | ||||||
- | - | - | - | - | - | 376 |
Deferred revenue | ||||||
107 | 1,387 | 377 | -578 | -860 | 1,624 | -1,096 |
Roche related-party deferred revenue | ||||||
5 | -5 | -3,742 | - | - | - | - |
Net cash used in operating activities | ||||||
-120,991 | -67,167 | -63,726 | -42,736 | -30,766 | -17,249 | - |
Net cash used in operating activities | ||||||
- | - | - | - | - | - | -14,133 |
Investing activities | ||||||
Purchases of property and equipment | ||||||
15,658 | 20,879 | 25,430 | 9,688 | 6,930 | 3,183 | 5,410 |
Purchases of marketable securities and other investments | ||||||
4,996 | 107,456 | 114,756 | - | - | - | - |
Proceeds from maturities of marketable securities | ||||||
84,390 | 141,023 | - | - | - | - | - |
Net cash (used in) provided by investing activities | ||||||
- | - | - | - | - | - | -5,410 |
Financing activities | ||||||
Change in restricted cash | ||||||
910 | - | 531 | -861 | 1,564 | - | - |
Net cash (used in) provided by investing activities | ||||||
62,826 | 12,688 | -140,717 | -8,827 | -8,494 | -3,183 | - |
Proceeds from issuance of common stock, net of issuance costs | ||||||
- | - | - | - | 110,381 | - | - |
Proceeds from indebtedness to Roche | ||||||
60,000 | - | - | - | - | - | - |
Net cash provided by financing activities | ||||||
- | - | - | - | - | - | 28,986 |
Proceeds from issuance of restricted stock and stock option exercises | ||||||
5,963 | 652 | 4,739 | 637 | 49 | 70 | 114 |
Payment of debt issuance costs | ||||||
14 | 319 | - | - | - | - | - |
Proceeds from issuance of notes payable | ||||||
- | - | - | - | - | - | 2,974 |
Payments of notes payable | ||||||
- | - | - | 1,287 | 1,705 | 1,569 | 440 |
Proceeds from issuance of Series B Preferred Stock, net of issuance costs | ||||||
- | - | - | - | 10 | - | - |
Net cash provided by financing activities | ||||||
65,949 | 333 | 250,126 | -650 | 108,715 | 64,418 | - |
Effect of exchange rate changes on cash and cash equivalents | ||||||
3 | - | - | - | - | - | - |
Supplemental disclosure of non-cash investing and financing activities | ||||||
Net increase (decrease) in cash and cash equivalents | ||||||
7,787 | -54,146 | 45,683 | -52,213 | 69,455 | 43,986 | 9,443 |
Cash paid for interest | ||||||
545 | 77 | - | 263 | 171 | 305 | 308 |
Conversion of convertible preferred stock into common stock | ||||||
- | - | - | - | 98,787 | - | - |
Acquisition of property and equipment included in accounts payable and accrued expenses | ||||||
4,098 | 2,029 | 6,822 | 1,334 | 3,916 | 1,070 | 816 |
Reclassification of warrant liability to additional paid-in capital | ||||||
- | - | - | - | 1,605 | - | - |
Accretion of convertible preferred stock to redemption value | ||||||
- | - | - | - | 139 | 286 | 296 |
Settlement of investor rights obligation | ||||||
- | - | - | - | - | - | 2,331 |